Navigation Links
University Hospitals Case Medical Center to begin clinical trial on experimental anti-TB drug
Date:7/29/2011

University Hospitals (UH) Case Medical Center will begin a Phase 1 clinical trial on a new experimental anti-tuberculosis drug called TMC207. This drug represents the first new class of anti-TB drugs in the past 60 years and it has activity against both drug-susceptible and drug-resistant TB.

The study is the first trial under a seven-year, $16.8 million contract awarded from the National Institutes of Health through the Hinckley-based research organization research organization Clinical Research Management (CRM) to UH Case Medical Center, Case Western Reserve University and Johns Hopkins University for first- in-human studies of new drugs for emerging infectious diseases.

TMC207 will be tested in 32 healthy individuals for its safety and tolerability, and to determine if its pharmacological activity is affected by repeat doses of other anti-TB drugs, rifabutin and rifampin, which are already in use and are often used in combination for treating TB.

The study will be led by Dr. Robert Salata, chief of the Division of Infectious Diseases at UH Case Medical Center and professor of medicine at Case Western Reserve University School of Medicine.

TB remains a major scourge. One third of the world's population is thought to be infected with it.


'/>"/>

Contact: George Stamatis
george.stamatis@uhhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1

Related medicine news :

1. University of Houston student awarded Hogg Foundation Scholarship
2. University of Leicester develops test for classifying force used in bottle stabbings
3. University of Maryland researchers discover possible drug targets for common non-Hodgkins lymphoma
4. Columbia University Medical Center receives $38.9 million to help translate science into treatment
5. Wayne State University engineering student receives American Tinnitus Association award
6. Mainz University Medical Center deploys new system for therapy of metastatic spinal tumors
7. Wayne State University researcher argues that sex reduces genetic variation
8. New book by Indiana University physicians slays health myths we all thought were true
9. Health providers should emphasize breast cancer screening, Wayne State University research finds
10. Researchers at Oregon Health & Science University discover MS-like disease in monkeys
11. Religion benefits traumatic brain injury victims, Wayne State University research finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 ... ... the Workers Compensation Research Institute (WCRI) officially opened registration today for its ... Place Hotel in Boston, MA . , The theme of the conference is ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: